In recent years there has been an increase in studies aimed at detecting differences between primary tumours and their metastases and between clones of cells with high or low metastatic potential. Cell surface carbohydrate expression appears to be related to metastatic potential and differences in cell surface carbohydrates have been demonstrated with animal tumours selected for high and low metastatic sublines Steck & Nicolson, 1983) . The importance of carbohydrate expression in malignant cells has also been highlighted by work with monoclonal antibodies. Monoclonal antibodies reactive with breast carcinoma have been shown to recognize determinants which are on high molecular weight glycoproteins , though the precise structure of these determinants is still unknown. Currently, differences in cell surface carbohydrate expression are detected using lectins and in a number of studies with human breast cancer tissues such differences have been shown to be of prognostic significance.
In a 20-year retrospective study, found Helix pomatia agglutinin (HPA) binding to be associated with metastasis to local lymph node in premenopausal women. Another finding relating HPA binding to lymph node stage, time to locoregional recurrence and to survival, and also Ulex europeus (UEA I) binding to disease-free interval and survival was reported by . Concanavalin A (Con A) binding has also been implicated in disease progression in primary cultures of breast cancer cells (Furmanski et al., 1981) . Con A reactivity was also reported to be negative in normal breast tissue, whereas positive Con A binding was related to stage and disease-free survival . However, in a multivariate analysis the differences in Con A binding were explained by the association with the stage of the disease . In the same report, peanut (Arachis hypogea) lectin (PNA) and wheat germ agglutinin (WGA) binding was found not to correlate with the clinical outcome. A significant correlation has also been reported between decreased WGA reactivity and the presence of lymph node metastasis . However, another study reported no differences in WGA binding to breast carcinomas with, or without, axillary lymph node involvement . With the exception of the study of Furmanski et al. (1981) as well as being spilled. Cell suspensions from both these samples showed similar staining for both HPA and Con A.
A sample from reduction mammoplasty served as the source of normal breast tissue. Cells from this tissue sample were cultured by the method of before staining with the lectins. The tissue mass was treated with collagenase (15 mg, Worthington Biochemical Corp.) at 37°C overnight and then washed with RPMI 1640 medium and seeded in two 25 cm tissue culture flasks containing RPMI 1640 medium and 10% fetal calf serum. Three weeks later considerable growth of breast epithelial tissue was observed in one of the flasks. Cells were removed with brief trypsin treatment and assessed for Class 1 MHC antigens to ensure that cell surface proteins had not been damaged by this. A single cell suspension from this culture was prepared by passing the cells through a 21G needle (Becton Dickinson). Cells were washed and stained as described for the tumour and node cells.
Flow cytometry
All flow cytometric studies of lectin binding were carried out on a FACScan (Becton Dickinson), using the Facscan Research software for analysis. Fluorescein isothiocyanate (FITC)-conjugated Helix pomatia (HPA) lectin and biotinylated succinyl concanavalin A (Con A) lectin, purchased from Sigma Chemical Co., were used at a concentration of 1 yg ml-'. Spilled cells from tumour and lymph node were washed twice in phosphate-buffered saline (PBS) and then resuspended in 50pl of PBS. The cell suspension was incubated with 100 p1 of the lectin solution on ice for 30 minutes in the dark and then washed twice in PBS. Cell suspensions treated with biotinylated Con A were further labelled with streptavidin-phycoerythrin (PE) (Becton Dickinson) by adding 10,l of streptavidin-PE solution per test and incubating for 20 minutes. All cell suspensions were washed in PBS and finally resuspended in 500 p1 PBS; 10p1l of propidium iodide (1 ig ml-') were added before acquisition to provide live/dead discrimination. Controls were included with each batch of tissue processed to give autofluorescence of tumour and node cells. 10,000 events per test were acquired with a gate on fluorescence channel 3 (propidium iodide), to acquire only the live cells in the suspension, and a live scatter gate on side scatter (SSC) vs forward scatter (FSC) was used to gate out the lymphocyte population (Figures la and lb). The SSC vs FSC gate was essential with cell suspension from lymph node as it invariably contained a high percentage of lymphocytes. Near absence (<5%) of lymphocytes in the acquired lymph node suspension was confirmed using a 'leucogate' antibody (Becton Dickinson).
Sugar inhibition was used to assess the specificity of lectin binding. A separate tube was treated identically except for the addition of the appropriate sugar (0.1 M).
Statistical analysis of the data was by the Wilcoxon Signed Rank Test and the x2 test. Table I . Only node involvement could be significantly related to HPA binding (P = 0.001). Though only 5 out of 23 patients of known age were of the premenopausal group, the percentage of positive HPA binding (60%) was considerably higher in this group in comparison to the postmenopausal group (39%). The difference is, however, statistically not significant (X2 test).
As shown in Table I , a significant positive correlation is observed between HPA binding and lymph node involvement (P = 0.001). Only 2 (15%) of a total of 13 node negative tumours were positive for HPA binding cells, whereas 85% (11 of 13) of the tumours with involved nodes were positive for HPA binding. Both the positive HPA patients in the node negative group had grade II tumours and one of them was in the premenopausal age group. The two negative HPA patients in the node positive group had grade I tumour and were both in the premenopausal age group.
The relationship between HPA binding and tumour grade is shown in Table I Figure 2f is the profile of the normal breast tissue, having a small proportion of the cells (18%), which were positive for HPA binding, doubly labelled (quadrant 2, Figure 2f ), while the rest of the cells are bound exclusively to Con A (quadrant 1, Figure 2f ). Though each tumour displayed a characterisitc profile of HPA/Con A binding cell distribution, roughly four distinct features appeared when all the analysed samples were considered. It is interesting to note that three tumour samples showed binding patterns consistent with Figure 2b , where the tumours had >70% cells which bound exclusively to HPA (quadrant 4, Figure 2b ) and all of these samples were from grade III tumours with involved node. If the two node-negative tumours which were positive for HPA binding are excluded, Figure 2e appears to be representative of node-negative tumours, which included all the four grade I tumours as well as some grade II and III tumours. Another group with a higher intensity of Con A binding (not shown) could also be included in the 2e group. Figure 2c and 2d includes node-positive tumours of grade II and III and two of the node-negative tumours which were high on HPA binding. There was, therefore, no consistent positive or negative correlation between HPA binding and Con A binding.
Analysis of spilled tumour cells from the lymph node In an attempt to see if high binding HPA or Con A cells could also be detected in the lymph node, spilled cells from all available lymph nodes were analysed for lectin binding. For subsequent correlation with histopathology, only nodes which were involved and for which tumour samples were also available were chosen. It is of interest to note that all noninvolved node samples were negative for HPA binding (data not shown) and no relationship was observed with Con A binding.
There were 12 involved lymph node samples with varying percentages of involved nodes available for analysis and for each of these node samples autologous primary tumour samples were also analysed. To assess the relationship between HPA binding tumour cells in involved lymph nodes and the number of nodes involved, all the cases with involved nodes were grouped into having either less than, or greater than, 50% of examined nodes involved. As shown in Table III (Figure lb) .
HPA has binding specificity for terminal N-acetyl galactosamine (GalNac) residues and an elevated level of GalNac expression in breast cancer suggests that the abnormality probably lies in the glycosylation pathways. Alteration in protein glycosylation has previously been linked to malignancy . Therapeutic applications can, therefore, be targeted towards glycosylating enzymes. Identification of defects in the precise step or steps in the glycosylation pathways would contribute to such applications. In this study, the binding of Con A and HPA were directly compared in a simultaneous two-colour flow cytometric study. HPA has specificity for terminal GalNAc groups and therefore has the potential to bind to the N-and 0-linked glycans of glycoproteins. Con A has specificity for terminal mannose or* glucose groups and might therefore be reasonably regarded as a specific marker of the N-linked oligosaccharide groups of glycoproteins.
The fact that HPA binding positivity in the lymph node is related to node involvement which, in turn, is related to HPA binding in tumours, provides a potential for the clinical exploitation of HPA binding as a metastatic phenotype. found HPA binding especially valuable in predicting prognosis independently of tumour grade and lymph node status, in addition to its application
